Epinoma

Executive Summary

Epinoma is a San Diego-based biotechnology company founded in 2018, focused on unlocking deep insights into the epigenome through its proprietary EpiAmp technology—the first methyl-preserving amplification chemistry. This innovative approach enables superior tools for epigenetic analysis, potentially driving new paradigms in disease detection and therapeutic development. Currently at the pre-clinical stage, the company is developing its platform to address unmet needs in epigenetics, a field with growing relevance in oncology, liquid biopsy, and precision medicine. While no financial details or pipeline specifics are disclosed, Epinoma's technology positions it as a promising player in the genetics and genomics sector. The company's early-stage status implies high risk but significant upside if its platform achieves validation. Key upcoming catalysts include progress toward lead candidate selection, initiation of early feasibility studies, and potential strategic partnerships or funding rounds to advance its EpiAmp technology toward clinical application.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026Collaboration with Academic or Pharma Partner for Epigenetic Assay Development60% success
• Q1 2027First Pre-clinical Data Release for EpiAmp in Oncology Model50% success